Statements (71)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:depression
|
| gptkbp:associated_with |
gptkb:Television_personality
gptkb:epilepsy gptkb:depression gptkb:neurodegenerative_diseases gptkb:multiple_sclerosis Huntington's disease emotional regulation decision making motivation stroke substance abuse aggression cognitive function schizophrenia anxiety disorders bipolar disorder neuroinflammation traumatic brain injury ADHD neuroplasticity stress response cardiovascular health pain perception sleep regulation social behavior oxidative stress emotional resilience cognitive flexibility aging process mood disorders neuroprotection hormonal regulation psychological well-being impulsivity appetite regulation synaptic transmission risk-taking behavior executive function learning and memory reward processing autism spectrum disorders cellular apoptosis |
| gptkbp:character_traits |
MAOA-u VNTR
|
| gptkbp:chromosome |
X chromosome
|
| gptkbp:clinical_trial |
target for antidepressants
target for anxiolytics |
| gptkbp:function |
breaks down neurotransmitters
|
| gptkbp:fuselage_material |
norepinephrine
dopamine serotonin |
| https://www.w3.org/2000/01/rdf-schema#label |
MAO-A
|
| gptkbp:inhibitor_example |
gptkb:Isocarboxazid
gptkb:Phenelzine gptkb:Selegiline gptkb:Tranylcypromine |
| gptkbp:initiated_by |
increases dopamine levels
MAO-A inhibitors increases norepinephrine levels increases serotonin levels |
| gptkbp:is_expressed_in |
placenta
brain tissue liver tissue |
| gptkbp:location |
outer mitochondrial membrane
|
| gptkbp:pathway |
neurotransmitter degradation
neurotransmitter metabolism oxidative deamination |
| gptkbp:promoter |
MAOA
|
| gptkbp:role |
regulating monoamine levels
|
| gptkbp:bfsParent |
gptkb:MAO
|
| gptkbp:bfsLayer |
7
|